Les Newsletters de Stop-Tabac.ch

Webmasters - Proposez nos news sur votre site

Rechercher dans les anciennes newsletter:

25 septembre 2012

La newsletter de stop-tabac: les sujets clés de l?actualité mondiale sur le tabagisme

Sélection réalisée par Jean-François Etter

Le 25 septembre 2012


- Un projet néo-zélandais dont la Suisse et la France devraient s'inspirer (Tutanga)
- Votez pour l'appli Stop-tabac pour le Swiss App of the Year Award
- Screening for lung cancer: we still need to know more
- Chattez avec un médecin tabacologue


Un projet néo-zélandais dont la Suisse et la France devraient s'inspirer (Tutanga)

Le gouvernement NZ a fixé comme objectif une réduction de la prévalence du tabagisme à 5% de la population, et finance une fondation pour piloter et monitorer ce projet:

http://www.turanga.org.nz (12 09 2012)
(25 09 2012)


Votez pour l'appli Stop-tabac pour le Swiss App of the Year Award

Veuillez installer l'appli Stop-tabac sur votre iPhone puis voter sur le site de Swisscom pour le concours Swiss App of the Year Award.
L'URL pour voter est :
http://labs.swisscom.ch/en/survey/scaya12-voting-ios

Il faut (malheureusement) créer un compte sur le site pour voter. (18 09 2012)
(25 09 2012)


Screening for lung cancer: we still need to know more

The holy grail for a screening test is that it discovers more cancers in the screened arm than in the control; that those cancers are of an earlier stage and there is, as a consequence, a stage shift towards lower stage cancers compared with the control group; that the test is acceptable to, basically, healthy individuals with low risks of serious side effects resulting from tests following a positive screen; and that the cost of a life saved, or a quality-adjusted life-year (QALY) is acceptable to the economy of the day...

The Danish trial confirms that lead time and possibly length time bias will identify more early cancers if sought by a sensitive test, but it is too early to arrive at any conclusion about an effect on reducing mortality. This, and the other current trials, may have to be studied by a meta-analysis to see how they compare with the huge NLST, which for the present suggests that CT-based screening is worthwhile. However, cost pressures, especially with the high cost of QALY for CT screening, will drive us to a better identification of the population to screen. Even then there are challenges, both methodological, in persuading the right' people to accept a screen, in interpreting the true from false-positive results, and in driving the costs of these expensive methods down. Finally, one may have to wait several years to find whether discovering more cancers early means more lives saved.

Thorax doi:10.1136/thoraxjnl-2011-201541 - Published Online First: 14 February 2012

Stephen G Spiro

http://thorax.bmj.com/content/early/2012/02/13/thoraxjnl-2011-201541.extract (20 02 2012)
(25 09 2012)



Retour à la liste des newsletters